Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1

Status

Completed 27Unknown 13Recruiting 8Terminated 6Active not recruiting 4Not yet recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 11Pancreatic Neoplasms 6Nasopharyngeal Carcinoma 5Cholangiocarcinoma 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Cirrhosis, Familial, with Pulmonary Hypertension 3Stomach Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Urinary Bladder Neoplasms 1Rare Tumour 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasms 1Neoplasm, Residual 1Neoadjuvant Chemotherapy 1Muscle Neoplasms 1Locally Advanced Low Rectal Adenocarcinoma 1Liver Neoplasms 1Liver Metastases of Colorectal Cancer 1Keratosis, Actinic 1HER2-positive Gastric Cancer 1Gastrointestinal Neoplasms 1

Interventions

toripalimab 6130-nm albumin-bound paclitaxel 6Cisplatin 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Neoadjuvant Therapy 2Esophagectomy 2Capecitabine 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1fluzoparib 1Watchful Waiting 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Paclitaxel 1Observation 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × Fluorouracil × Clear all
NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
90 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07251062 2025-11-26

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2/3 Not yet recruiting
737 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Sun Yat-sen University

Phase 3 Not yet recruiting
360 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡